GALAPAGOS NV (GLPGF)
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Address
GEN DE WITTELAAN L11 A3
2800 MECHELEN, C9 00000
Founded
1999
Number of Employees
1,123
Website
http://www.glpg.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)